NCT03960593

Brief Summary

Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 6, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2019

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 21, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 23, 2019

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2024

Completed
Last Updated

May 23, 2019

Status Verified

May 1, 2019

Enrollment Period

2 months

First QC Date

May 21, 2019

Last Update Submit

May 21, 2019

Conditions

Cancer and / or Hematological Malignancy

Outcome Measures

Primary Outcomes (1)

  • Geriatric Assessment (EGS) on Geriatric HDJ

    Inclusion in HDJ and geriatric frailty collection (EGS) by the geriatrician in HDJ. Evaluation by pharmacist and collection in HDJ of the usual treatment, phytotherapy, future oncological treatment administered. Geriatric and pharmaceutical report in 24 hours sent to the treating physician and oncologist

    3-6 moths

Study Arms (1)

Patients with cancer and / or hematological

The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.

Other: Evaluation of the influence of geriatric factors

Interventions

Evaluation of the influence of geriatric factorsOTHER

Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.

Patients with cancer and / or hematological

Eligibility Criteria

Age70 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.

You may qualify if:

  • Subjects over the age of 70 with an Oncoding score less than or equal to 14
  • Patients receiving social security benefits
  • suffering from cancerous pathology whatever the stage / grade and the associated comorbidities treated by chemotherapy and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy
  • Having read, understood and signed the non-opposition form

You may not qualify if:

  • Patients refusing to participate in the research project
  • Patients under guardianship or curatorship
  • Patients who are not beneficiaries of a social security scheme

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

RECRUITING

Related Publications (1)

  • Couderc AL, Ninove L, Nouguerede E, Rey D, Rebroin M, Daumas A, Tomasini P, Greillier L, Salas S, Duffaud F, Dahan L, Duluc M, Garcia ME, Pluvy J, Chaleat S, Farnault L, Venton G, Fourie T, Nurtop E, de Lamballerie X, Villani P, Charrel R, Correard F. Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer. J Geriatr Oncol. 2022 Jul;13(6):850-855. doi: 10.1016/j.jgo.2022.05.002. Epub 2022 May 16.

    PMID: 35589542DERIVED

MeSH Terms

Conditions

NeoplasmsHematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2019

First Posted

May 23, 2019

Study Start

November 6, 2018

Primary Completion

January 1, 2019

Study Completion

May 6, 2024

Last Updated

May 23, 2019

Record last verified: 2019-05

Locations

FR(1)